India  

COVID-19 Pills May Conflict With Certain Medications, Study Finds

Video Credit: Wibbitz Top Stories - Duration: 01:30s - Published
COVID-19 Pills May Conflict With Certain Medications, Study Finds

COVID-19 Pills May Conflict With Certain Medications, Study Finds

COVID-19 Pills May Conflict With , Certain Medications, Study Finds.

NBC News reports experts are warning anti-viral pills created by Pfizer and Merck may not be safe for everyone.

Recently cleared by the Food and Drug Administration to treat infections in patients 12 and older, anti-viral pills have been a cause for optimism in the fight against COVID-19.

According to NBC News, experts have found that certain ingredients in the anti-viral pills may cause extreme reactions when paired with more widely-used medications.

Oddly enough, many of the affected medications are widely prescribed to those with the highest risk of developing COVID-19 complications.

Oddly enough, many of the affected medications are widely prescribed to those with the highest risk of developing COVID-19 complications.

These medications include antidepressants, immunosuppressants and even inhalers.

These medications include antidepressants, immunosuppressants and even inhalers.

Some of these potential interactions are not trivial, and some pairings have to be avoided altogether.

, Peter Anderson, professor of pharmaceutical science, University of Colorado, via NBC News.

Some of these potential interactions are not trivial, and some pairings have to be avoided altogether.

, Peter Anderson, professor of pharmaceutical science, University of Colorado, via NBC News.

Some are probably easily managed.

But some we’re going to have to be very careful about.

, Peter Anderson, professor of pharmaceutical science, University of Colorado, via NBC News.

Some are probably easily managed.

But some we’re going to have to be very careful about.

, Peter Anderson, professor of pharmaceutical science, University of Colorado, via NBC News.

Amid concerns, experts remain excited by the potential of anti-viral pills.

This could make a real difference in the pandemic by making an effective Covid treatment available to many people.

, Peter Anderson, professor of pharmaceutical science, University of Colorado, via NBC News.

This could make a real difference in the pandemic by making an effective Covid treatment available to many people.

, Peter Anderson, professor of pharmaceutical science, University of Colorado, via NBC News


You Might Like


💡 newsR Knowledge: Other News Mentions

COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

‘What was there to celebrate?’: Voters react to partygate [Video]

‘What was there to celebrate?’: Voters react to partygate

Westminster is still reeling from Sue Gray’s damning report into partygate, which found multiple breaches of Covid rules in Downing Street. The prime minister has said he takes “full responsibility” but is keen to move on - as are many Tory MPs - but what about voters? Report by Burnsla. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn

Credit: ODN    Duration: 02:59Published
After 2 years of COVID, Peru's clowns return [Video]

After 2 years of COVID, Peru's clowns return

After being suspended for two years due to COVID-19 hundreds of clowns dressed in colorful costumes, wigs and face paint marched through the streets of central Lima on Wednesday to celebrate Peruvian Clown Day.

Credit: euronews (in English)    Duration: 01:00Published
Covid-19 infections jump significantly, 2,628 cases reported in 24 hours | OneIndia News [Video]

Covid-19 infections jump significantly, 2,628 cases reported in 24 hours | OneIndia News

India reported 2,628 fresh Covid-19 cases in the past 24 hours, a significant jump in the last 24 hours. The number of infections is 23.7 per cent higher than that reported on Wednesday. With this the Covid-19 case toll in the country has reached 4,31,44,820. #Covid19 #Covid19Cases #India

Credit: Oneindia    Duration: 01:27Published

University of Colorado Boulder University of Colorado Boulder Public university in Colorado, U.S.

Astronomers Discover Rare Reversed Black Hole For the First Time [Video]

Astronomers Discover Rare Reversed Black Hole For the First Time

Astronomers Discover Rare, Reversed Black Hole , For the First Time. 'The Independent' reports that NASA has detected what they believe to be the spontaneous reversal of a black hole's magnetic poles. . Rapid changes in visible and ultraviolet light have been seen in a few dozen galaxies similar to this one, Sibasish Laha, Research scientist at the University of Maryland, Baltimore County and Nasa’s Goddard Space Flight Center, via 'The Independent'. But this event marks the first time we’ve seen X-rays dropping out completely while the other wavelengths brighten, Sibasish Laha, Research scientist at the University of Maryland, Baltimore County and Nasa’s Goddard Space Flight Center, via 'The Independent'. Astronomers first noticed that a galaxy called 1ES1927+654 had brightened by nearly 100 times in March 2018. . Astronomers first noticed that a galaxy called 1ES1927+654 had brightened by nearly 100 times in March 2018. . According to further research, the eruption had begun at the end of 2017. . It was very exciting to delve into this galaxy’s strange explosive episode and try to understand the possible physical processes at work, José Acosta-Pulido, Co-author at the Canary Islands Institute of Astrophysics, via 'The Independent'. 'The Independent' reports that a supermassive black hole resides at the center of most large galaxies. According to astronomers, the magnetic field of the black hole is what creates and sustains the corona, a cloud of extremely hot particles that produce high-energy x-rays. A magnetic reversal, where the north pole becomes south and vice versa, seems to best fit the observations. The field initially weakens at the outskirts of the accretion disk, leading to greater heating and brightening in visible and UV light, Mitchell Begelman, Co-author and professor in the department of astrophysical and planetary sciences at the University of Colorado Boulder, via 'The Independent'. The team's findings have been accepted for publication in 'The Astrophysical Journal.'

Credit: Wibbitz Top Stories    Duration: 01:31Published

Pfizer Pfizer American multinational pharmaceutical corporation

COVID-19 is more worrying than monkeypox, says Pfizer boss

New COVID variants that might evade current vaccines are a greater threat to global public health than the monkeypox outbreak, the chief executive of Pfizer has..
Sky News
Pfizer’s 3-Dose Vaccine 80% Effective Against Omicron Infection for Youngest Children [Video]

Pfizer’s 3-Dose Vaccine 80% Effective Against Omicron Infection for Youngest Children

Pfizer’s 3-Dose Vaccine , 80% Effective Against Omicron, Infection for Youngest Children. ABC News reports new data shows Pfizer's 3-dose vaccine is 80% effective against omicron infections in children five years old and younger. In all age groups, Pfizer's coronavirus vaccine has been less effective against mild breakthrough infections. but has been shown to offer high protection against severe disease and death. Experts say Pfizer's announcement offers reassurance to parents who wish to protect their children against coronavirus. We are pleased that our formulation for the youngest children, which we carefully selected to be one-tenth of the dose strength for adults ... , statement from Albert Bourla, chairman CEO Pfizer, via ABC News. ... was well tolerated and produced a strong immune response. , statement from Albert Bourla, chairman CEO Pfizer, via ABC News. After two years without a vaccine for young children, many pediatricians and parents intend to vaccinate as soon as possible. However, recent polls have shown over 50% of parents feel they need more information before their children receive a COVID-19 shot. Parents should also be aware that this preliminary data will be supplemented by additional data in June ... , Dr. Alok Patel, pediatric hospitalist Stanford Children's Health, via ABC News. ... which will then be thoroughly reviewed by both the FDA and the CDC. , Dr. Alok Patel, pediatric hospitalist Stanford Children's Health, via ABC News

Credit: Wibbitz Top Stories    Duration: 01:30Published
CDC Signs Off on COVID Vaccine Boosters for Kids Ages 5–11 [Video]

CDC Signs Off on COVID Vaccine Boosters for Kids Ages 5–11

CDC Signs Off on COVID Vaccine Boosters , for Kids Ages 5–11. CNN reports that on May 19, the CDC's Advisory Committee on Immunization Practices (ACIP)... . ... voted in support of recommending an additional Pfizer shot for 5- to 11-year-olds who've received their first two doses. The vote was 11-1 with 1 abstention. CNN reports that the FDA authorized the booster dose earlier this week. Children within this age group are advised to wait at least five months after receiving their two-dose regimen before getting a booster shot. CNN reports a fourth dose is recommended for children who are immunocompromised. . According to Pfizer, a trial of 4,500 children ages 5-11 showed Omicron-fighting antibodies were 36 times stronger upon receiving a booster. The company also says no new safety issues were detected. On May 16, the American Academy of Pediatrics reported that COVID cases in U.S. children rose 76% the previous week compared to two weeks prior. CDC Director Dr. Rochelle Walensky gave opening remarks before the ACIP's vote. The sadness I feel for lives lost, the families devastated and the communities changed is steep. We have the tools we need to protect these people from severe disease and prevent any more tragic deaths, Dr. Rochelle Walensky, via opening remarks before the ACIP's vote, via CNN

Credit: Wibbitz Top Stories    Duration: 01:31Published
Pfizer’s COVID Booster Shot for 5 to 11 Year Olds Authorized by FDA [Video]

Pfizer’s COVID Booster Shot for 5 to 11 Year Olds Authorized by FDA

Pfizer’s COVID Booster Shot , for 5 to 11 Year Olds, Authorized by FDA. NBC News reports on May 17, the Food and Drug Administration (FDA)... … announced it had authorized Pfizer-BioNTech's coronavirus booster dose for 5 to 11 year olds. The FDA says eligible recipients of a booster dose could receive the extra shot starting five months after their initial two-dose series. Per NBC News, Pfizer's booster shot for 5 to 11 year olds is 10 micrograms ... . ... a third of the dosage given to citizens 12 and older. Following the FDA's ruling, it is now up to the Centers for Disease Control and Prevention (CDC) to recommend how to implement boosters for the age group. CDC data shows less than one third of 5 to 11 year olds in the United States have recieved the primary series of a COVID-19 vaccine. Experts say booster shots offer better protection against the omicron strain and its associated subvariants. The CDC's Advisory Committee on Immunization Practices will reportedly discuss booster shots on May 19. Dr. Rochelle Walensky, the Director of the CDC, should have her final recommendation following the committee's discussion

Credit: Wibbitz Top Stories    Duration: 01:30Published
Pfizer's First Quarter Profits Blast Past 2022 Forecast [Video]

Pfizer's First Quarter Profits Blast Past 2022 Forecast

Pfizer's First Quarter , Profits Blast Past, 2022 Forecast. ABC reports that Pfizer's COVID-19 vaccine and treatment sales helped propel the pharmaceuticals company beyond Wall Street's first quarter expectations. . Pfizer's coronavirus vaccine Comirnaty raked in over $13 billion in sales for the first quarter. . Pfizer's coronavirus vaccine Comirnaty raked in over $13 billion in sales for the first quarter. . The vaccine has remained Pfizer's top selling product for almost the last year. . The drugmaker's pill treatment Paxloid reportedly added an additional $1.5 billion to the company's sales. . ABC reports that Pfizer's, profits grew 61% , in the first quarter. . On May 3, the company posted a net income of $7.86 billion and first quarter adjusted earnings of $1.62 per share. . The results easily exceeded the $1.49 increase predicted by industry analysts. . Compared to the same time last year, the company's revenue skyrocketed 77% , to reach $25.66 billion. . According to ABC, the drugmaker expects the company's total revenue in 2022 to reach between $98 billion and $102 billion. . Pfizer's COVID vaccine launched late in 2020 and quickly became the company's top selling product by the second quarter of 2021. In December of 2021, Pfizer's stock reached an all-time high of $61.71 per share.

Credit: Wibbitz Top Stories    Duration: 01:31Published

Food and Drug Administration Food and Drug Administration Agency of the US Department of Health and Human Services

FDA lifts hold on Covaxin's clinical trials in US

The US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's Covid-19 vaccine Covaxin, in USA, has lifted the..
IndiaTimes

Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold

The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19..
IndiaTimes
Biden Invokes Defense Powers to Address Baby Formula Shortage [Video]

Biden Invokes Defense Powers to Address Baby Formula Shortage

Biden Invokes Defense Powers , to Address Baby Formula Shortage. President Joe Biden invoked the Defense Production Act on May 18. “Operation Fly Formula” will make use of planes owned by the Defense Department to assist in the distribution of baby formula. The planes will be deployed both nationally and internationally. I know parents all across the country are worried about finding enough infant formula to feed their babies — , President Joe Biden, via 'The New York Times'. ... as a parent and as a grandparent, I know just how stressful that is, President Joe Biden, via 'The New York Times'. [I have directed my administration] to do everything possible to ensure there’s enough safe baby formula.., President Joe Biden, via 'The New York Times'. ... and that it’s quickly reaching families that need it the most, President Joe Biden, via 'The New York Times'. In this case, the Defense Production Act allows the president to order companies to prioritize the production and distribution of baby formula. . The House of Representatives approved $28 million in emergency funds to address the shortage. It also approved a bill that would ease restrictions on the types of formula that can be purchased through federal aid programs geared toward women and children. I know what it means to not be able to stretch out milk for the entire month, Rep. Jahana Hayes, (CA-D), via 'The New York Times'. With everything going on right now, the last thing a family should have to worry about is feeding their children, Rep. Jahana Hayes, (CA-D), via 'The New York Times'. This is so basic. Everyone understands that we’re all on high alert here, and this is an incredible emergency, Sen. Debbie Stabenow, (MI-D), via 'The New York Times'. While the emergency funds did not receive overwhelming bipartisan support, the bill to ease baby formula purchasing restrictions did. The emergency funds would allow the U.S. Food and Drug Administration to increase its ability to oversee companies that produce baby formula. Both measures are expected to pass in the Senate

Credit: Wibbitz Top Stories    Duration: 01:31Published